Steve Harvey/LinkedIn
Sep 19, 2025, 06:06
Aspirin as Precision Medicine? Steve Harvey Highlights Evidence for PIK3-Mutated Colorectal Cancer Patients
Steve Harvey, CEO of Camena Bioscience, shared a post on LinkedIn:
“A very interesting study indicates that Aspirin could be a precision medicine for colorectal cancer.
The study, which was publicised in the New England Journal of Medicine, studied 3500 patients with colorectal cancer.
~40% of those patients had mutations in genes associated with the PIK3 signalling pathway.
Those patients with the PIK3 associated mutations and taking aspirin, were 55% less likely to have the cancer return than those on placebo.
P.s. I’ll add the Guardian article to the comments.”
You can read the full article here.
More posts featured in Hemostasis Today.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants